<VariationArchive VariationID="6912" VariationName="NM_003002.4(SDHD):c.337_340del (p.Asp113fs)" VariationType="Deletion" Accession="VCV000006912" Version="21" RecordType="classified" NumberOfSubmissions="7" NumberOfSubmitters="7" DateLastUpdated="2024-07-29" DateCreated="2013-04-04" MostRecentSubmission="2024-05-01">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="21951" VariationID="6912">
      <GeneList>
        <Gene Symbol="SDHD" FullName="succinate dehydrogenase complex subunit D" GeneID="6392" HGNC_ID="HGNC:10683" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>11q23.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="112086873" stop="112095794" display_start="112086873" display_stop="112095794" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="11" Accession="NC_000011.9" start="111957570" stop="111966517" display_start="111957570" display_stop="111966517" Strand="+" />
          </Location>
          <OMIM>602690</OMIM>
          <Haploinsufficiency last_evaluated="2021-08-11" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=SDHD">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-08-11" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=SDHD">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_003002.4(SDHD):c.337_340del (p.Asp113fs)</Name>
      <CanonicalSPDI>NC_000011.10:112094823:ACTGACT:ACT</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>11q23.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="112094824" stop="112094827" display_start="112094824" display_stop="112094827" variantLength="4" positionVCF="112094823" referenceAlleleVCF="TACTG" alternateAlleleVCF="T" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="11" Accession="NC_000011.9" start="111965548" stop="111965551" display_start="111965548" display_stop="111965551" variantLength="4" positionVCF="111965547" referenceAlleleVCF="TACTG" alternateAlleleVCF="T" />
      </Location>
      <ProteinChange>D113fs</ProteinChange>
      <ProteinChange>D74fs</ProteinChange>
      <ProteinChange>T65fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_9" sequenceAccession="LRG_9">
            <Expression>LRG_9:g.12981_12984del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000011.10" sequenceAccession="NC_000011" sequenceVersion="10" change="g.112094827_112094830del" Assembly="GRCh38">
            <Expression>NC_000011.10:g.112094827_112094830del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000011.9" sequenceAccession="NC_000011" sequenceVersion="9" change="g.111965551_111965554del" Assembly="GRCh37">
            <Expression>NC_000011.9:g.111965551_111965554del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_012337.3" sequenceAccession="NG_012337" sequenceVersion="3" change="g.12981_12984del">
            <Expression>NG_012337.3:g.12981_12984del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001276503.2" sequenceAccession="NM_001276503" sequenceVersion="2" change="c.192_195del">
            <Expression>NM_001276503.2:c.192_195del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001263432.1" sequenceAccession="NP_001263432" sequenceVersion="1" change="p.Thr65fs">
            <Expression>NP_001263432.1:p.Thr65fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001276504.2" sequenceAccession="NM_001276504" sequenceVersion="2" change="c.220_223del">
            <Expression>NM_001276504.2:c.220_223del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001263433.1" sequenceAccession="NP_001263433" sequenceVersion="1" change="p.Asp74fs">
            <Expression>NP_001263433.1:p.Asp74fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001276506.2" sequenceAccession="NM_001276506" sequenceVersion="2" change="c.*35_*38del">
            <Expression>NM_001276506.2:c.*35_*38del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001624" Type="3 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_003002.4" sequenceAccession="NM_003002" sequenceVersion="4" change="c.337_340del" MANESelect="true">
            <Expression>NM_003002.4:c.337_340del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_002993.1" sequenceAccession="NP_002993" sequenceVersion="1" change="p.Asp113fs">
            <Expression>NP_002993.1:p.Asp113fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="non-coding">
          <NucleotideExpression sequenceAccessionVersion="NR_077060.2" sequenceAccession="NR_077060" sequenceVersion="2" change="n.426_429del">
            <Expression>NR_077060.2:n.426_429del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001619" Type="non-coding transcript variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_003002.3" sequenceAccession="NM_003002" sequenceVersion="3" change="c.337_340del">
            <Expression>NM_003002.3:c.337_340del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_9t1" sequenceAccession="LRG_9t1">
            <Expression>LRG_9t1:c.337_340del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_9p1" sequenceAccession="LRG_9p1" change="p.Asp113fs">
            <Expression>LRG_9p1:p.Asp113fs</Expression>
          </ProteinExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_003002.4" sequenceAccession="NM_003002" sequenceVersion="4" change="c.337_340delGACT" MANESelect="true">
            <Expression>NM_003002.4:c.337_340delGACT</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="Allelic variant" ID="602690.0022" DB="OMIM" />
        <XRef Type="rs" ID="587776648" DB="dbSNP" />
        <XRef ID="CA016955" DB="ClinGen" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_003002.4(SDHD):c.337_340del (p.Asp113fs) AND Paragangliomas 1" Accession="RCV000007321" Version="13">
        <ClassifiedConditionList TraitSetID="1900">
          <ClassifiedCondition DB="MedGen" ID="C3494181">Paragangliomas 1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-04-17" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_003002.4(SDHD):c.337_340del (p.Asp113fs) AND not provided" Accession="RCV000485947" Version="15">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2023-08-15" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_003002.4(SDHD):c.337_340del (p.Asp113fs) AND multiple conditions" Accession="RCV002228011" Version="13">
        <ClassifiedConditionList TraitSetID="73586">
          <ClassifiedCondition DB="MedGen" ID="C1847319">Carney-Stratakis syndrome</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="CN166604">Cowden syndrome 3</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1868633">Paragangliomas with sensorineural hearing loss</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0031511">Pheochromocytoma</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-04-25" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_003002.4(SDHD):c.337_340del (p.Asp113fs) AND Hereditary cancer-predisposing syndrome" Accession="RCV002453249" Version="9">
        <ClassifiedConditionList TraitSetID="13598">
          <ClassifiedCondition DB="MedGen" ID="C0027672">Hereditary cancer-predisposing syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-06-07" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_003002.4(SDHD):c.337_340del (p.Asp113fs) AND multiple conditions" Accession="RCV002504760" Version="8">
        <ClassifiedConditionList TraitSetID="66138">
          <ClassifiedCondition DB="MedGen" ID="C1847319">Carney-Stratakis syndrome</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C5436934">Mitochondrial complex 2 deficiency, nuclear type 3</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C3494181">Paragangliomas 1</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0031511">Pheochromocytoma</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-09-06" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-08-15" NumberOfSubmissions="7" NumberOfSubmitters="7" DateCreated="2013-04-04" MostRecentSubmission="2024-05-01">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">12111639</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">15328326</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">15905695</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">16314641</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">16317055</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">17102082</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">17848412</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">19393419</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20208144</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21348866</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22517554</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24735130</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">27539324</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="66138" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="3796" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Chromaffinoma</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Chromaffin paraganglioma</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Chromaffin tumor</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Medullary paraganglioma</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Chromaffin cell tumor</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Pheochromocytoma</ElementValue>
                <XRef ID="Pheochromocytoma/5718" DB="Genetic Alliance" />
                <XRef ID="HP:0002666" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0008233" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15105" />
                <XRef ID="15105" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">SDHB-Related Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">SDHD-Related Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">KIF1B-Related Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">MAX-Related Susceptibility to Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">VHL-Related Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">MAX-Related Hereditary Paraganglioma-Pheochromocytoma Syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Hereditary paraganglioma-pheochromocytoma (PGL/PCC) syndromes are characterized by paragangliomas (tumors that arise from neuroendocrine tissues distributed along the paravertebral axis from the base of the skull to the pelvis) and pheochromocytomas (paragangliomas that are confined to the adrenal medulla). Sympathetic paragangliomas cause catecholamine excess; parasympathetic paragangliomas are most often nonsecretory. Extra-adrenal parasympathetic paragangliomas are located predominantly in the skull base and neck (referred to as head and neck PGL [HNPGL]) and sometimes in the upper mediastinum; approximately 95% of such tumors are nonsecretory. In contrast, sympathetic extra-adrenal paragangliomas are generally confined to the lower mediastinum, abdomen, and pelvis, and are typically secretory. Pheochromocytomas, which arise from the adrenal medulla, typically lead to catecholamine excess. Symptoms of PGL/PCC result from either mass effects or catecholamine hypersecretion (e.g., sustained or paroxysmal elevations in blood pressure, headache, episodic profuse sweating, forceful palpitations, pallor, and apprehension or anxiety). The risk for developing metastatic disease is greater for extra-adrenal sympathetic paragangliomas than for pheochromocytomas.</Attribute>
                <XRef ID="NBK1548" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">TMEM127-Related Susceptibility to Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">RET-Related Pheochromocytoma</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301715</ID>
                <ID Source="BookShelf">NBK1548</ID>
              </Citation>
              <Citation Type="general" Abbrev="ES, 2014">
                <ID Source="PubMed">24893135</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="general" Abbrev="NANETS, 2010">
                <ID Source="PubMed">20664475</ID>
                <ID Source="pmc">3419007</ID>
              </Citation>
              <Citation Type="general" Abbrev="KCRNC, 2013">
                <ID Source="PubMed">24319509</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Endocrine and Neuroendocrine Neoplasia genetics">
                <ID Source="PubMed">26389271</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="NANETS, 2021">
                <ID Source="PubMed">33939658</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Neuroendocrine and Adrenal Tumors, 2023</CitationText>
              </Citation>
              <XRef ID="29072" DB="Orphanet" />
              <XRef ID="C0031511" DB="MedGen" />
              <XRef ID="MONDO:0008233" DB="MONDO" />
              <XRef Type="MIM" ID="171300" DB="OMIM" />
              <XRef Type="primary" ID="HP:0002666" DB="Human Phenotype Ontology" />
            </Trait>
            <Trait ID="3265" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Carney-Stratakis syndrome</ElementValue>
                <XRef ID="MONDO:0011740" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Paraganglioma and gastrointestinal stromal tumor</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Paraganglioma and GIST</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Carney-Stratakis dyad of paraganglioma and gastric stromal sarcoma</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Carney dyad</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Paraganglioma and gastric stromal sarcoma</ElementValue>
                <XRef ID="Paraganglioma+and+gastric+stromal+sarcoma/5577" DB="Genetic Alliance" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10643" />
                <XRef ID="10643" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Endocrine and Neuroendocrine Neoplasia genetics">
                <ID Source="PubMed">26389271</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2024">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Soft Tissue Sarcoma, 2024</CitationText>
              </Citation>
              <XRef ID="97286" DB="Orphanet" />
              <XRef ID="C1847319" DB="MedGen" />
              <XRef ID="MONDO:0011740" DB="MONDO" />
              <XRef Type="MIM" ID="606864" DB="OMIM" />
            </Trait>
            <Trait ID="55762" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Mitochondrial complex 2 deficiency, nuclear type 3</ElementValue>
                <XRef ID="MONDO:0030937" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">MITOCHONDRIAL COMPLEX II DEFICIENCY, NUCLEAR TYPE 3</ElementValue>
                <XRef Type="MIM" ID="619167" DB="OMIM" />
                <XRef Type="Allelic variant" ID="602690.0029" DB="OMIM" />
                <XRef Type="Allelic variant" ID="602690.0030" DB="OMIM" />
                <XRef Type="Allelic variant" ID="602690.0031" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">MC2DN3</ElementValue>
                <XRef Type="MIM" ID="619167" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="16430" />
                <XRef ID="16430" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="C5436934" DB="MedGen" />
              <XRef ID="MONDO:0030937" DB="MONDO" />
              <XRef Type="MIM" ID="619167" DB="OMIM" />
            </Trait>
            <Trait ID="5731" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Paragangliomas 1</ElementValue>
                <XRef ID="Paragangliomas+1/5578" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Paraganglioma - glomus jugulare</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Paragangliomata</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glomus tumors familial 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">PARAGANGLIOMAS, FAMILIAL NONCHROMAFFIN, 1</ElementValue>
                <XRef Type="MIM" ID="168000" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">PGL 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Paragangliomas familial 1</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">PPGL1</ElementValue>
                <XRef Type="MIM" ID="168000" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">PGL</ElementValue>
                <XRef Type="MIM" ID="168000" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">CBT1</ElementValue>
                <XRef Type="MIM" ID="168000" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">PGL1</ElementValue>
                <XRef Type="MIM" ID="168000" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7324" />
                <XRef ID="7324" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Hereditary paraganglioma-pheochromocytoma (PGL/PCC) syndromes are characterized by paragangliomas (tumors that arise from neuroendocrine tissues distributed along the paravertebral axis from the base of the skull to the pelvis) and pheochromocytomas (paragangliomas that are confined to the adrenal medulla). Sympathetic paragangliomas cause catecholamine excess; parasympathetic paragangliomas are most often nonsecretory. Extra-adrenal parasympathetic paragangliomas are located predominantly in the skull base and neck (referred to as head and neck PGL [HNPGL]) and sometimes in the upper mediastinum; approximately 95% of such tumors are nonsecretory. In contrast, sympathetic extra-adrenal paragangliomas are generally confined to the lower mediastinum, abdomen, and pelvis, and are typically secretory. Pheochromocytomas, which arise from the adrenal medulla, typically lead to catecholamine excess. Symptoms of PGL/PCC result from either mass effects or catecholamine hypersecretion (e.g., sustained or paroxysmal elevations in blood pressure, headache, episodic profuse sweating, forceful palpitations, pallor, and apprehension or anxiety). The risk for developing metastatic disease is greater for extra-adrenal sympathetic paragangliomas than for pheochromocytomas.</Attribute>
                <XRef ID="NBK1548" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301715</ID>
                <ID Source="BookShelf">NBK1548</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2010">
                <ID Source="PubMed">20065170</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2009">
                <ID Source="pmc">2668639</ID>
              </Citation>
              <Citation Type="review">
                <ID Source="PubMed">20816580</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="general" Abbrev="ES, 2014">
                <ID Source="PubMed">24893135</ID>
              </Citation>
              <Citation Type="general" Abbrev="NANETS, 2010">
                <ID Source="PubMed">20664475</ID>
                <ID Source="pmc">3419007</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="KCRNC, 2013">
                <ID Source="PubMed">24319509</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2015">
                <ID Source="PubMed">26324357</ID>
              </Citation>
              <Citation Type="general" Abbrev="NANETS, 2021">
                <ID Source="PubMed">33939658</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Neuroendocrine and Adrenal Tumors, 2023</CitationText>
              </Citation>
              <XRef ID="29072" DB="Orphanet" />
              <XRef ID="C3494181" DB="MedGen" />
              <XRef ID="MONDO:0008192" DB="MONDO" />
              <XRef Type="MIM" ID="168000" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="73586" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17663" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Cowden syndrome 3</ElementValue>
                <XRef ID="MONDO:0014045" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">CWS3</ElementValue>
              </Symbol>
              <XRef ID="201" DB="Orphanet" />
              <XRef ID="CN166604" DB="MedGen" />
              <XRef ID="MONDO:0014045" DB="MONDO" />
            </Trait>
            <Trait ID="8850" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Paragangliomas with sensorineural hearing loss</ElementValue>
              </Name>
              <XRef ID="C1868633" DB="MedGen" />
            </Trait>
            <Trait ID="3796" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Chromaffinoma</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Chromaffin paraganglioma</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Chromaffin tumor</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Medullary paraganglioma</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Chromaffin cell tumor</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Pheochromocytoma</ElementValue>
                <XRef ID="Pheochromocytoma/5718" DB="Genetic Alliance" />
                <XRef ID="HP:0002666" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0008233" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15105" />
                <XRef ID="15105" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">SDHB-Related Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">SDHD-Related Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">KIF1B-Related Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">MAX-Related Susceptibility to Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">VHL-Related Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">MAX-Related Hereditary Paraganglioma-Pheochromocytoma Syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Hereditary paraganglioma-pheochromocytoma (PGL/PCC) syndromes are characterized by paragangliomas (tumors that arise from neuroendocrine tissues distributed along the paravertebral axis from the base of the skull to the pelvis) and pheochromocytomas (paragangliomas that are confined to the adrenal medulla). Sympathetic paragangliomas cause catecholamine excess; parasympathetic paragangliomas are most often nonsecretory. Extra-adrenal parasympathetic paragangliomas are located predominantly in the skull base and neck (referred to as head and neck PGL [HNPGL]) and sometimes in the upper mediastinum; approximately 95% of such tumors are nonsecretory. In contrast, sympathetic extra-adrenal paragangliomas are generally confined to the lower mediastinum, abdomen, and pelvis, and are typically secretory. Pheochromocytomas, which arise from the adrenal medulla, typically lead to catecholamine excess. Symptoms of PGL/PCC result from either mass effects or catecholamine hypersecretion (e.g., sustained or paroxysmal elevations in blood pressure, headache, episodic profuse sweating, forceful palpitations, pallor, and apprehension or anxiety). The risk for developing metastatic disease is greater for extra-adrenal sympathetic paragangliomas than for pheochromocytomas.</Attribute>
                <XRef ID="NBK1548" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">TMEM127-Related Susceptibility to Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">RET-Related Pheochromocytoma</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301715</ID>
                <ID Source="BookShelf">NBK1548</ID>
              </Citation>
              <Citation Type="general" Abbrev="ES, 2014">
                <ID Source="PubMed">24893135</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="general" Abbrev="NANETS, 2010">
                <ID Source="PubMed">20664475</ID>
                <ID Source="pmc">3419007</ID>
              </Citation>
              <Citation Type="general" Abbrev="KCRNC, 2013">
                <ID Source="PubMed">24319509</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Endocrine and Neuroendocrine Neoplasia genetics">
                <ID Source="PubMed">26389271</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="NANETS, 2021">
                <ID Source="PubMed">33939658</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Neuroendocrine and Adrenal Tumors, 2023</CitationText>
              </Citation>
              <XRef ID="29072" DB="Orphanet" />
              <XRef ID="C0031511" DB="MedGen" />
              <XRef ID="MONDO:0008233" DB="MONDO" />
              <XRef Type="MIM" ID="171300" DB="OMIM" />
              <XRef Type="primary" ID="HP:0002666" DB="Human Phenotype Ontology" />
            </Trait>
            <Trait ID="3265" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Carney-Stratakis syndrome</ElementValue>
                <XRef ID="MONDO:0011740" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Paraganglioma and gastrointestinal stromal tumor</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Paraganglioma and GIST</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Carney-Stratakis dyad of paraganglioma and gastric stromal sarcoma</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Carney dyad</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Paraganglioma and gastric stromal sarcoma</ElementValue>
                <XRef ID="Paraganglioma+and+gastric+stromal+sarcoma/5577" DB="Genetic Alliance" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10643" />
                <XRef ID="10643" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Endocrine and Neuroendocrine Neoplasia genetics">
                <ID Source="PubMed">26389271</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2024">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Soft Tissue Sarcoma, 2024</CitationText>
              </Citation>
              <XRef ID="97286" DB="Orphanet" />
              <XRef ID="C1847319" DB="MedGen" />
              <XRef ID="MONDO:0011740" DB="MONDO" />
              <XRef Type="MIM" ID="606864" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="1900" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5731" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Paragangliomas 1</ElementValue>
                <XRef ID="Paragangliomas+1/5578" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Paraganglioma - glomus jugulare</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Paragangliomata</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glomus tumors familial 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">PARAGANGLIOMAS, FAMILIAL NONCHROMAFFIN, 1</ElementValue>
                <XRef Type="MIM" ID="168000" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">PGL 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Paragangliomas familial 1</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">PPGL1</ElementValue>
                <XRef Type="MIM" ID="168000" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">PGL</ElementValue>
                <XRef Type="MIM" ID="168000" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">CBT1</ElementValue>
                <XRef Type="MIM" ID="168000" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">PGL1</ElementValue>
                <XRef Type="MIM" ID="168000" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7324" />
                <XRef ID="7324" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Hereditary paraganglioma-pheochromocytoma (PGL/PCC) syndromes are characterized by paragangliomas (tumors that arise from neuroendocrine tissues distributed along the paravertebral axis from the base of the skull to the pelvis) and pheochromocytomas (paragangliomas that are confined to the adrenal medulla). Sympathetic paragangliomas cause catecholamine excess; parasympathetic paragangliomas are most often nonsecretory. Extra-adrenal parasympathetic paragangliomas are located predominantly in the skull base and neck (referred to as head and neck PGL [HNPGL]) and sometimes in the upper mediastinum; approximately 95% of such tumors are nonsecretory. In contrast, sympathetic extra-adrenal paragangliomas are generally confined to the lower mediastinum, abdomen, and pelvis, and are typically secretory. Pheochromocytomas, which arise from the adrenal medulla, typically lead to catecholamine excess. Symptoms of PGL/PCC result from either mass effects or catecholamine hypersecretion (e.g., sustained or paroxysmal elevations in blood pressure, headache, episodic profuse sweating, forceful palpitations, pallor, and apprehension or anxiety). The risk for developing metastatic disease is greater for extra-adrenal sympathetic paragangliomas than for pheochromocytomas.</Attribute>
                <XRef ID="NBK1548" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301715</ID>
                <ID Source="BookShelf">NBK1548</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2010">
                <ID Source="PubMed">20065170</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2009">
                <ID Source="pmc">2668639</ID>
              </Citation>
              <Citation Type="review">
                <ID Source="PubMed">20816580</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="general" Abbrev="ES, 2014">
                <ID Source="PubMed">24893135</ID>
              </Citation>
              <Citation Type="general" Abbrev="NANETS, 2010">
                <ID Source="PubMed">20664475</ID>
                <ID Source="pmc">3419007</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="KCRNC, 2013">
                <ID Source="PubMed">24319509</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2015">
                <ID Source="PubMed">26324357</ID>
              </Citation>
              <Citation Type="general" Abbrev="NANETS, 2021">
                <ID Source="PubMed">33939658</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Neuroendocrine and Adrenal Tumors, 2023</CitationText>
              </Citation>
              <XRef ID="29072" DB="Orphanet" />
              <XRef ID="C3494181" DB="MedGen" />
              <XRef ID="MONDO:0008192" DB="MONDO" />
              <XRef Type="MIM" ID="168000" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="13598" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="18746" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Tumor predisposition</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cancer predisposition</ElementValue>
                <XRef ID="Hereditary+Cancer/3345" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary neoplastic syndrome</ElementValue>
                <XRef ID="MONDO:0015356" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary Cancer Syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Neoplastic Syndromes, Hereditary</ElementValue>
                <XRef ID="D009386" DB="MeSH" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hereditary cancer-predisposing syndrome</ElementValue>
                <XRef ID="699346009" DB="SNOMED CT" />
              </Name>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="19921" />
                <XRef ID="19921" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <Citation Type="general" Abbrev="IARC, 2008">
                <ID Source="pmc">3075918</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <XRef ID="140162" DB="Orphanet" />
              <XRef ID="C0027672" DB="MedGen" />
              <XRef ID="D009386" DB="MeSH" />
              <XRef ID="MONDO:0015356" DB="MONDO" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="7519709" SubmissionDate="2023-07-25" DateLastUpdated="2023-07-29" DateCreated="2023-07-29">
        <ClinVarSubmissionID localKey="102495543|OMIM:168000" />
        <ClinVarAccession Accession="SCV004018064" DateUpdated="2023-07-29" DateCreated="2023-07-29" Type="SCV" Version="1" SubmitterName="Myriad Genetics, Inc." OrgID="507240" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-04-17">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Myriad Autosomal Dominant, Autosomal Recessive and X-Linked Classification Criteria (2023)</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/8ufcwsf2/myriad_genetics_classification_criteria_2023.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SDHD" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="hg19" Chr="11" alternateAllele="T" referenceAllele="TGACT" start="111965550" stop="111965554" />
          </Location>
          <OtherNameList>
            <Name Type="SubmitterVariantId">102495543</Name>
          </OtherNameList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="168000" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13707487</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1845856" SubmissionDate="2024-02-15" DateLastUpdated="2024-02-28" DateCreated="2019-08-14">
        <ClinVarSubmissionID localKey="4331458|MedGen:C1847319;C1868633;C0031511;C3554516" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000951739" DateUpdated="2024-02-28" DateCreated="2019-08-14" Type="SCV" Version="6" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-04-25">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">12111639</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">17848412</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21348866</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22517554</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27539324</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 6912). This variant is also known as 13732delGACT. This premature translational stop signal has been observed in individuals with paragangliomas and/or pheochromocytomas (PMID: 12111639, 17848412, 21348866, 22517554, 27539324). It has also been observed to segregate with disease in related individuals. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Asp113Metfs*21) in the SDHD gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 47 amino acid(s) of the SDHD protein.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SDHD" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000011.9:g.111965548_111965551del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease" multipleConditionExplanation="Uncertain">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1847319" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1868633" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0031511" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C3554516" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14224806</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="27519" SubmissionDate="2019-07-24" DateLastUpdated="2024-05-01" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="602690.0022_PHEOCHROMOCYTOMA/PARAGANGLIOMA SYNDROME 1" title="SDHD, 4-BP DEL, 13732GACT_PHEOCHROMOCYTOMA/PARAGANGLIOMA SYNDROME 1" />
        <ClinVarAccession Accession="SCV000027519" DateUpdated="2024-05-01" DateCreated="2013-04-04" Type="SCV" Version="3" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2002-08-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In an apparently sporadic case of pheochromocytoma and paraganglioma (PPGL1; 168000), Cascon et al. (2002) identified a heterozygous 4-bp frameshift deletion in exon 4 of the SDHD gene (13732delGACT), resulting in a truncated protein of 132 amino acids.</Attribute>
              <Citation>
                <ID Source="PubMed">12111639</ID>
              </Citation>
              <XRef DB="OMIM" ID="168000" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SDHD" />
          </GeneList>
          <Name>SDHD, 4-BP DEL, 13732GACT</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">4-BP DEL, 13732GACT</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="602690.0022" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">PHEOCHROMOCYTOMA/PARAGANGLIOMA SYNDROME 1</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1100656" SubmissionDate="2019-01-29" DateLastUpdated="2017-12-19" DateCreated="2017-04-27">
        <ClinVarSubmissionID localKey="GDX:57135|Not Provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000565549" DateUpdated="2017-12-19" DateCreated="2017-04-27" Type="SCV" Version="5" SubmitterName="GeneDx" OrgID="26957" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-04-16">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>This deletion of four nucleotides in SDHD is denoted c.337_340delGACT at the cDNA level and p.Asp113MetfsX21 (D113MfsX21) at the protein level. The normal sequence, with the bases that are deleted in brackets, is TACT[delGACT]ATGT. The deletion causes a frameshift, which changes an Aspartic Acid to a Methionine at codon 113, and creates a premature stop codon at position 21 of the new reading frame. This variant is predicted to cause loss of normal protein function through protein truncation as the last 47 amino acids are no longer translated. The disrupted region includes the helical transmembrane topological domain and the ubiquinone binding site (UniProt). This variant, also known as SDHD c.334_337delACTG, is a recurrent variant that has been reported in many individuals with early-onset and/or multiple paragangliomas/pheochromocytomas, and has been shown to track with disease in several families (Cascon 2002, Velasco 2005, Benn 2006, Lima 2007, Hermsen 2010, Lefebvre 2012). Paragangliomas from individuals carrying this variant have demonstrated loss of SDHB by IHC, and functional assays have shown that this variant results in a significant reduction of SDH enzyme activity and SDHB protein expression (Rapizzi 2012, Pai 2014). We consider this variant to be pathogenic. Of note, variants in the SDHD gene exhibit a parent-of-origin effect and, if shown to be pathogenic, typically cause symptoms only if inherited from the father.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">GeneDx Variant Classification (06012015)</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/dhtz9flo/genedx_interprules_final_061215.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SDHD" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_003002.2:c.337_340delGACT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not Provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB5098196</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5464616" SubmissionDate="2022-12-13" DateLastUpdated="2022-12-31" DateCreated="2022-12-31">
        <ClinVarSubmissionID localKey="NM_003002.4:c.337_340del|OMIM:168000;171300;606864;619167" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002810507" DateUpdated="2022-12-31" DateCreated="2022-12-31" Type="SCV" Version="1" SubmitterName="Fulgent Genetics, Fulgent Genetics" OrgID="500105" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-09-06">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_003002.4:c.337_340del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="TraitChoice">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="168000" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="171300" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="606864" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="619167" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12390657</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4991700" SubmissionDate="2023-08-16" DateLastUpdated="2023-08-18" DateCreated="2022-07-30">
        <ClinVarSubmissionID localKey="NM_003002.4:c.337_340delGACT|not provided" />
        <ClinVarAccession Accession="SCV002549996" DateUpdated="2023-08-18" DateCreated="2022-07-30" Type="SCV" Version="4" SubmitterName="Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital" OrgID="505691" OrganizationCategory="laboratory" OrgAbbreviation="GM4113, RH" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-08-15">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SDHD" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_003002.4:c.337_340delGACT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11858215</SubmissionName>
          <SubmissionName>SUB13715930</SubmissionName>
          <SubmissionName>SUB13716033</SubmissionName>
          <SubmissionName>SUB13754379</SubmissionName>
          <SubmissionName>SUB13762356</SubmissionName>
          <SubmissionName>SUB13765301</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5098181" SubmissionDate="2024-04-24" DateLastUpdated="2024-05-01" DateCreated="2022-11-29">
        <ClinVarSubmissionID localKey="a8263844|MedGen:C0027672" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002614297" DateUpdated="2024-05-01" DateCreated="2022-11-29" Type="SCV" Version="2" SubmitterName="Ambry Genetics" OrgID="61756" OrganizationCategory="laboratory" OrgAbbreviation="Ambry" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-06-07">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">12111639</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15328326</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15905695</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">16314641</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">16317055</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">17102082</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">17848412</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">19393419</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20208144</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21348866</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22517554</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24735130</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27539324</ID>
          </Citation>
          <Comment>The c.337_340delGACT pathogenic mutation, located in coding exon 4 of the SDHD gene, results from a deletion of 4 nucleotides at nucleotide positions 337 to 340, causing a translational frameshift with a predicted alternate stop codon (p.D113Mfs*21). This variant has been reported in many individuals with paragangliomas and/or pheochromocytomas (Cascon A et al. Eur J Hum Genet, 2002 Aug;10:457-61; Neumann HP et al. JAMA, 2004 Aug;292:943-51; Amar L et al. J Clin Oncol, 2005 Dec;23:8812-8; Velasco A et al. Diagn Mol Pathol, 2005 Jun;14:109-14; Benn DE et al. J Clin Endocrinol Metab, 2006 Mar;91:827-36; Castellano M et al. Ann N Y Acad Sci, 2006 Aug;1073:156-65; Lima J et al. J Clin Endocrinol Metab, 2007 Dec;92:4853-64; Sevilla MA et al. Otolaryngol Head Neck Surg, 2009 May;140:724-9; Hermsen MA et al. Cell Oncol, 2010 Jan;32:275-83; Hensen EF et al. Clin Genet, 2012 Mar;81:284-8; Lefebvre S et al. Horm Metab Res, 2012 May;44:334-8; Pai R et al. APMIS, 2014 Nov;122:1130-5; Pandit R et al. Eur J Endocrinol, 2016 Oct;175:311-23). This variant is also referred to as SDHD 13732delGACT and SDHD c.334_337delACTG in the literature. This alteration occurs at the 3' terminus of theSDHD gene, is not expected to trigger nonsense-mediated mRNA decay, and only impacts the last 29% of the protein. However, premature stop codons are typically deleterious in nature and the impacted region is critical for protein function (Ambry internal data). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Ambry Variant Classification Scheme 2023</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/i9igeqse/ambry_variant_classification_scheme_2023.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SDHD" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_003002.2:c.337_340delGACT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0027672" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>All AVA3 Novel and Update Variants_103122</SubmissionName>
          <SubmissionName>FinalClinVarSubmissionFile_20140101to20240315_ava3_1</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1845856" TraitType="Disease" MappingType="XRef" MappingValue="C1847319" MappingRef="MedGen">
        <MedGen CUI="C1847319" Name="Carney-Stratakis syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5464616" TraitType="Disease" MappingType="XRef" MappingValue="606864" MappingRef="OMIM">
        <MedGen CUI="C1847319" Name="Carney-Stratakis syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="27519" TraitType="Disease" MappingType="Name" MappingValue="PHEOCHROMOCYTOMA/PARAGANGLIOMA SYNDROME 1" MappingRef="Preferred">
        <MedGen CUI="C3494181" Name="Paragangliomas 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7519709" TraitType="Disease" MappingType="XRef" MappingValue="168000" MappingRef="OMIM">
        <MedGen CUI="C3494181" Name="Paragangliomas 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5464616" TraitType="Disease" MappingType="XRef" MappingValue="168000" MappingRef="OMIM">
        <MedGen CUI="C3494181" Name="Paragangliomas 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1845856" TraitType="Disease" MappingType="XRef" MappingValue="C3554516" MappingRef="MedGen">
        <MedGen CUI="CN166604" Name="Cowden syndrome 3" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5464616" TraitType="Disease" MappingType="XRef" MappingValue="619167" MappingRef="OMIM">
        <MedGen CUI="C5436934" Name="Mitochondrial complex 2 deficiency, nuclear type 3" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4991700" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1845856" TraitType="Disease" MappingType="XRef" MappingValue="C0031511" MappingRef="MedGen">
        <MedGen CUI="C0031511" Name="Pheochromocytoma" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1100656" TraitType="Disease" MappingType="Name" MappingValue="Not Provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1845856" TraitType="Disease" MappingType="XRef" MappingValue="C1868633" MappingRef="MedGen">
        <MedGen CUI="C1868633" Name="Paragangliomas with sensorineural hearing loss" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5098181" TraitType="Disease" MappingType="XRef" MappingValue="C0027672" MappingRef="MedGen">
        <MedGen CUI="C0027672" Name="Hereditary cancer-predisposing syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5464616" TraitType="Disease" MappingType="XRef" MappingValue="171300" MappingRef="OMIM">
        <MedGen CUI="C0031511" Name="Pheochromocytoma" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

